Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Davis Comprehensive Cancer Center
Davis, California, United States
Tianhong (Tina) Li, MDRecruiting - Uci Health Chao Family Comprehensive Cancer Center
Irvine, California, United States
Cathleen Park, MDRecruiting - Recruiting
- Uc San Diego Moores Cancer Center
San Diego, California, United States
Sandip Patel, MDRecruiting - University of California at San Francisco
San Francisco, California, United States
Claire Mulvey, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Mar 2025
- Primary completion
- 24 Apr 2028
- Completion
- 24 Apr 2029
- Last update posted
- 18 May 2026
- Registered enrollment
- 29
- Registry id
- NCT06788938
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.